0001395064-20-000081.txt : 20200603
0001395064-20-000081.hdr.sgml : 20200603
20200603060725
ACCESSION NUMBER: 0001395064-20-000081
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190108
FILED AS OF DATE: 20200603
DATE AS OF CHANGE: 20200603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD
CENTRAL INDEX KEY: 0001395064
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 20938874
BUSINESS ADDRESS:
STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-8668
BUSINESS PHONE: 81332782111
MAIL ADDRESS:
STREET 1: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 103-8668
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
3
1
wf-form3_159117882285800.xml
FORM 3
X0206
3
2019-01-08
0
0001693415
Translate Bio, Inc.
TBIO
0001395064
TAKEDA PHARMACEUTICAL CO LTD
1-1, NIHONBASHI-HONCHO 2-CHOME
CHUO-KU, TOKYO
M0
103-8668
JAPAN
0
0
1
0
Common Stock A
7078945
I
See Explanation of Responses
These shares are owned directly by Shire Human Genetic Therapies, Inc. On January 8, 2019, Takeda Pharmaceutical Company Limited completed the acquisition of 100% of the issued and to-be-issued share capital of Shire plc pursuant to a Scheme of Arrangement under the laws of Jersey. Upon the completion of the Shire plc acquisition, Shire Human Genetic Therapies, Inc. became an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
/s/ Amit Singh, Senior Vice President and Head of Treasury of Takeda Pharmaceutical Company
Limited
2020-06-03